STOCK TITAN

[Form 4] Twist Bioscience Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Insider sale to cover taxes: The Form 4 shows that Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), had 23,747 shares of common stock sold on 10/06/2025 at $32.187 per share. The filing states these sales were mandatory "sell to cover" transactions to meet tax‑withholding obligations tied to vested Performance Stock Units (PSUs) and were not discretionary trades. After the transaction, the reporting person beneficially owned 208,735 shares. The sale was reported on 10/08/2025 and signed by an attorney‑in‑fact.

Vendita da insider per coprire le tasse: Il Form 4 mostra che Patrick John Finn, Presidente e COO di Twist Bioscience Corp (TWST), ha 23.747 azioni ordinarie vendute il 10/06/2025 a $32.187 per azione. L'atto segnala che queste vendite erano obbligatorie transazioni "vendere per coprire" per soddisfare gli obblighi di ritenuta fiscale legati alle PSU (Performance Stock Units) maturate e non erano operazioni discrezionali. Dopo la transazione, la persona reportante deteneva beneficiariamente 208.735 azioni. La vendita è stata riportata il 10/08/2025 e firmata da un procuratore.

Venta de insider para cubrir impuestos: El Form 4 muestra que Patrick John Finn, Presidente y COO de Twist Bioscience Corp (TWST), vendió 23,747 acciones comunes el 10/06/2025 a $32.187 por acción. El documento indica que estas ventas fueron transacciones obligatorias de "vender para cubrir" para cumplir con las obligaciones de retención de impuestos vinculadas a las PSU (Unidades de Acciones de Desempeño) adquiridas y no eran operaciones discrecionales. Después de la transacción, la persona reportante poseía beneficialmente 208,735 acciones. La venta fue reportada el 10/08/2025 y firmada por un apoderado.

세금 커버용 내부자 매도: Form 4에 따르면 Patrick John Finn, Twist Bioscience Corp (TWST) 의 회장 겸 COO가 23,747주를 2025/10/06$32.187 달러의 주당가로 매도했습니다. 신고서는 이 매도가 성문화된 보유 PSUs(성과주식단위)와 관련된 세금 원천징수 의무를 충족하기 위한 필수적 "매도하여 커버" 거래였으며 재량적 거래가 아니라고 명시합니다. 거래 후 보고자의 실제 보유 주식 수는 208,735주였습니다. 매도 건은 2025/10/08에 보고되었고 대리인에 의해 서명되었습니다.

Vente par initié pour couvrir les impôts : Le Form 4 indique que Patrick John Finn, Président et COO de Twist Bioscience Corp (TWST), a vendu 23 747 actions ordinaires le 10/06/2025 à $32.187 par action. Le dépôt précise que ces ventes étaient des transactions obligatoires « vendre pour couvrir » afin de respecter les obligations de retenue d'impôt liées aux unités d'actions de performance (PSU) acquises et n'étaient pas des transactions discrétionnaires. Après la transaction, la personne déclarant possédait bénéfi ciairement 208 735 actions. La vente a été déclarée le 10/08/2025 et signée par un mandataire.

Insider-Verkauf zur Deckung der Steuern: Das Formular 4 zeigt, dass Patrick John Finn, Präsident und COO von Twist Bioscience Corp (TWST), 23.747 Stammaktien verkauft hat am 10/06/2025 zu $32.187 pro Aktie. Der Einreichung zufolge waren diese Verkäufe obligatorische „sell to cover“-Transaktionen, um Steuerabzugsverpflichtungen im Zusammenhang mit vesteten PSUs (Performance Stock Units) zu erfüllen, und es handelte sich nicht um diskretionäre Trades. Nach der Transaktion besaß die meldende Person beneficially 208.735 Aktien. Der Verkauf wurde am 10/08/2025 gemeldet und von einer Bevollmächtigten unterzeichnet.

بيع داخلي لتغطية الضرائب: يُظهر النموذج 4 أن Patrick John Finn، الرئيس والـ COO لدى Twist Bioscience Corp (TWST)، باع 23,747 سهماً من الأسهم العادية في 2025/10/06 بسعر $32.187 للسهم. يذكر الإبلاغ أن هذه المبيعات كانت معاملات "بيع لتغطية" إلزامية لتلبية الالتزامات بالاقتطاع الضريبي المرتبطة بوحدات الأسهم المُحققة (PSUs) وليست صفقات تقديرية. بعد الصفقة، امتلك الشخص المُبلغ عنه فعلياً 208,735 سهماً. تم الإبلاغ عن البيع في 2025/10/08 وتوقيعها من قبل وكيل نيابة.

内幕交易以覆盖税款: 表格4显示,Patrick John Finn,Twist Bioscience Corp(TWST)的总裁兼首席运营官,出售了23,747股普通股,交易日期为2025/10/06,每股价格为$32.187。该申报表示这些出售为强制性的“卖出以覆盖”交易,以满足与已归属的绩效股票单位(PSU)相关的税款扣缴义务,而非自由裁量交易。交易后,申报人实际拥有208,735股。该出售于2025/10/08被报告,并由一名代理人签署。

Positive
  • Transaction was non-discretionary and executed to satisfy tax withholding from vested PSUs
  • Reporting shows substantial retained ownership with 208,735 shares remaining after the sale
Negative
  • Insider sold 23,747 shares, which modestly reduces immediate insider-held shares

Insights

Mandatory sell-to-cover tax sale reduced holdings by 23,747 shares.

The reported disposition on 10/06/2025 reflects a non-discretionary sale tied to tax withholding for vested PSUs, not an open-market diversification decision. The transaction price was $32.187 and the filing notes the company requires "sell to cover" under its equity plans.

Key near-term items to watch include any future PSU vesting schedules and additional Form 4 filings that would show discretionary sales or further mandatory withholdings; those would modify insider ownership trends over the next vesting cycles.

Vendita da insider per coprire le tasse: Il Form 4 mostra che Patrick John Finn, Presidente e COO di Twist Bioscience Corp (TWST), ha 23.747 azioni ordinarie vendute il 10/06/2025 a $32.187 per azione. L'atto segnala che queste vendite erano obbligatorie transazioni "vendere per coprire" per soddisfare gli obblighi di ritenuta fiscale legati alle PSU (Performance Stock Units) maturate e non erano operazioni discrezionali. Dopo la transazione, la persona reportante deteneva beneficiariamente 208.735 azioni. La vendita è stata riportata il 10/08/2025 e firmata da un procuratore.

Venta de insider para cubrir impuestos: El Form 4 muestra que Patrick John Finn, Presidente y COO de Twist Bioscience Corp (TWST), vendió 23,747 acciones comunes el 10/06/2025 a $32.187 por acción. El documento indica que estas ventas fueron transacciones obligatorias de "vender para cubrir" para cumplir con las obligaciones de retención de impuestos vinculadas a las PSU (Unidades de Acciones de Desempeño) adquiridas y no eran operaciones discrecionales. Después de la transacción, la persona reportante poseía beneficialmente 208,735 acciones. La venta fue reportada el 10/08/2025 y firmada por un apoderado.

세금 커버용 내부자 매도: Form 4에 따르면 Patrick John Finn, Twist Bioscience Corp (TWST) 의 회장 겸 COO가 23,747주를 2025/10/06$32.187 달러의 주당가로 매도했습니다. 신고서는 이 매도가 성문화된 보유 PSUs(성과주식단위)와 관련된 세금 원천징수 의무를 충족하기 위한 필수적 "매도하여 커버" 거래였으며 재량적 거래가 아니라고 명시합니다. 거래 후 보고자의 실제 보유 주식 수는 208,735주였습니다. 매도 건은 2025/10/08에 보고되었고 대리인에 의해 서명되었습니다.

Vente par initié pour couvrir les impôts : Le Form 4 indique que Patrick John Finn, Président et COO de Twist Bioscience Corp (TWST), a vendu 23 747 actions ordinaires le 10/06/2025 à $32.187 par action. Le dépôt précise que ces ventes étaient des transactions obligatoires « vendre pour couvrir » afin de respecter les obligations de retenue d'impôt liées aux unités d'actions de performance (PSU) acquises et n'étaient pas des transactions discrétionnaires. Après la transaction, la personne déclarant possédait bénéfi ciairement 208 735 actions. La vente a été déclarée le 10/08/2025 et signée par un mandataire.

Insider-Verkauf zur Deckung der Steuern: Das Formular 4 zeigt, dass Patrick John Finn, Präsident und COO von Twist Bioscience Corp (TWST), 23.747 Stammaktien verkauft hat am 10/06/2025 zu $32.187 pro Aktie. Der Einreichung zufolge waren diese Verkäufe obligatorische „sell to cover“-Transaktionen, um Steuerabzugsverpflichtungen im Zusammenhang mit vesteten PSUs (Performance Stock Units) zu erfüllen, und es handelte sich nicht um diskretionäre Trades. Nach der Transaktion besaß die meldende Person beneficially 208.735 Aktien. Der Verkauf wurde am 10/08/2025 gemeldet und von einer Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Finn Patrick John

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S 23,747(1) D $32.187 208,735 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TWST insider Patrick John Finn report on Form 4?

He reported a sale of 23,747 shares on 10/06/2025 at $32.187 per share to cover tax withholding from vested PSUs.

Was the share sale by the TWST executive discretionary?

No. The filing states the sales were mandated by the issuer's "sell to cover" election under its equity incentive plans and do not represent discretionary trades.

How many shares does the reporting person own after the transaction?

208,735 shares of TWST common stock are reported as beneficially owned following the transaction.

When was the Form 4 filed and who signed it?

The Form 4 was dated and signed on 10/08/2025 by an attorney-in-fact, indicating timely reporting of the 10/06/2025 transaction.

What triggered the sale of shares on TWST Form 4?

Tax withholding obligations associated with the vesting of Performance Stock Units triggered a mandatory "sell to cover" sale.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

1.88B
59.19M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO